US FDA Reveals DTC Enforcement Approach In Letter For AstraZeneca’s FluMist Ad

 
• By Derrick Gingery
  
FluMist, an intranasal flu vaccine, was the subject of a CBER advertising violation letter. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from United States